Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | TPH1 | P17752 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269305 | 1.00 | LOXL2 (0.43) | LOXL2TRPA1TAAR1MAOBDPP4 | |
| SCHEMBL12809801 | 1.00 | LOXL2 (0.43) | LOXL2TRPA1TAAR1MAOBDPP4 | |
| SCHEMBL13078008 | 0.83 | TP53 (0.35) | TAAR1 | |
| SCHEMBL8855721 | 0.83 | TSHR (0.39) | TAAR1 | |
| SCHEMBL9498462 | 0.81 | CYP3A4 (0.42) | LOXL2TAAR1MAOB | |
| SCHEMBL2269394 | 0.81 | CYP3A4 (0.42) | LOXL2TAAR1MAOB | |
| SCHEMBL6670843 | 0.81 | HRH3 (0.48) | LOXL2TAAR1 | |
| SCHEMBL6670839 | 0.81 | HRH3 (0.48) | LOXL2TAAR1 | |
| SCHEMBL242931 | 0.81 | CYP3A4 (0.42) | LOXL2TAAR1MAOB | |
| SCHEMBL24311641 | 0.79 | CYP1A2 (0.41) | DPP4IDO1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-0683792-B1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LAB (US) | 2001-09-26 | — | — | EP | claimed |
| EP-0673254-A4 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| EP-0683792-A4 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| US-5767082-A | ANTIFERTILITY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1998-06-16 | — | — | US | claimed |
| US-5698522-A | INHIBIT RELEASE OF LUTEINIZING HORMONE RELEASING HORMONE | ABBOTT LABORATORIES (US) | 1997-12-16 | — | — | US | claimed |
| JP-H09501913-A | — | — | 1997-02-25 | — | — | JP | claimed |
| EP-0738154-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | Abbott Laboratories (US) | 1996-10-23 | — | — | EP | claimed |
| JP-H08505611-A | — | — | 1996-06-18 | — | — | JP | claimed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0301850-A2 | LHRH antagonist analogs and 19-nor-progestational steroids for therapy | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
| EP-0277829-A2 | Nonapeptide and decapeptide analogs of LHRH as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1988-08-10 | — | — | EP | claimed |
| EP-0127899-B1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | The Administrators of The Tulane University Educational Fund (US) | 1987-10-21 | — | — | EP | claimed |
| EP-0188214-A2 | Novel growth hormone-releasing peptides and method of treating mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1986-07-23 | — | — | EP | claimed |
| EP-0145768-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY, David Howard (US) | 1985-06-26 | — | — | EP | claimed |
| WO-1984004916-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY DAVID HOWARD (US) | 1984-12-20 | — | — | WO | claimed |
| EP-0127899-A1 | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1984-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | LOXL2 4664/4885TRPA1 4475/4885TAAR1 478/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | LOXL2 4664/4885TRPA1 4475/4885TAAR1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.